<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18</volume><submitter>Kozlowska K</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Insulinomas are the most common functional pancreatic neuroendocrine tumors (pNETs). Minimally invasive approaches like endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and ethanol ablation (EUS-EA) are emerging treatment options for small insulinomas (&lt;2 cm).&lt;h4>Objectives&lt;/h4>To assess the safety, efficacy, and long-term outcomes of EUS-RFA and EUS-EA in treating small pancreatic insulinomas.&lt;h4>Design&lt;/h4>A retrospective, single-center study of nine patients diagnosed with insulinomas and treated with EUS ablation methods.&lt;h4>Methods&lt;/h4>Nine lesions (mean size 11 mm; range: 6-19 mm) were treated with EUS-RFA (&lt;i>n&lt;/i> = 7) or EUS-EA (&lt;i>n&lt;/i> = 2). EUS-RFA procedures had a mean ablation time of 31 s (range: 17-69 s), while EUS-EA used a mean ethanol vol</pubmed_abstract><journal>Therapeutic advances in gastrointestinal endoscopy</journal><pagination>26317745251401315</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12708985</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>EUS-guided radiofrequency and ethanol ablation of pancreatic insulinomas: a single-center experience.</pubmed_title><pmcid>PMC12708985</pmcid><pubmed_authors>Wiechowska-Kozlowska A</pubmed_authors><pubmed_authors>Bosy-Gasior W</pubmed_authors><pubmed_authors>Hsino-Sito N</pubmed_authors><pubmed_authors>Kozlowska K</pubmed_authors><pubmed_authors>Pawlak KM</pubmed_authors><pubmed_authors>Jedruszek S</pubmed_authors></additional><is_claimable>false</is_claimable><name>EUS-guided radiofrequency and ethanol ablation of pancreatic insulinomas: a single-center experience.</name><description>&lt;h4>Background&lt;/h4>Insulinomas are the most common functional pancreatic neuroendocrine tumors (pNETs). Minimally invasive approaches like endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) and ethanol ablation (EUS-EA) are emerging treatment options for small insulinomas (&lt;2 cm).&lt;h4>Objectives&lt;/h4>To assess the safety, efficacy, and long-term outcomes of EUS-RFA and EUS-EA in treating small pancreatic insulinomas.&lt;h4>Design&lt;/h4>A retrospective, single-center study of nine patients diagnosed with insulinomas and treated with EUS ablation methods.&lt;h4>Methods&lt;/h4>Nine lesions (mean size 11 mm; range: 6-19 mm) were treated with EUS-RFA (&lt;i>n&lt;/i> = 7) or EUS-EA (&lt;i>n&lt;/i> = 2). EUS-RFA procedures had a mean ablation time of 31 s (range: 17-69 s), while EUS-EA used a mean ethanol vol</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan-Dec</publication><modification>2026-06-08T05:08:55.745Z</modification><creation>2026-06-08T03:09:10.161Z</creation></dates><accession>S-EPMC12708985</accession><cross_references><pubmed>41415532</pubmed><doi>10.1177/26317745251401315</doi></cross_references></HashMap>